HYQTD Drug-containing Serum Alleviates H2O2-induced Endothelial Oxidative Damage by Increasing Mitochondrial ATP Synthesis and Inhibiting ROS.

Background: Atherosclerosis (AS) is caused by the endothelium injury associated with oxidative stress. Previous studies have shown that the Phlegm-Eliminating and Stasis- Transforming Decoction (Huayu Qutan Decoction, HYQTD) has mitochondrial protective function. The objective of this research was to explore how HYQTD drug-containing serum (HYQTD-DS) could potentially protect mitochondrial energy production in endothelial cells (ECs) from injury caused by hydrogen peroxide (H2O2)-induced oxidative damage in AS through SIRT1/PGC-1α/ Nrf2 pathway.

A combined treatment regimen for infection in in southern China.

The Sichuan snub-nosed monkey () is an endangered species in China and is susceptible to infection with species. However, the worms are difficult to remove completely. A practical treatment regimen for trichuriasis was conducted over a seven-month period on 15  in a wildlife zoo in southern China.

Warming-driven migration of enterotypes mediates host health and disease statuses in ectotherm Litopenaeus vannamei.

Global warming has threatened all-rounded hierarchical biosphere by reconstructing eco-structure and bringing biodiversity variations. Pacific white shrimp, a successful model of worldwide utilizing marine ectothermic resources, is facing huge losses due to multiple diseases relevant to intestinal microbiota (IM) dysbiosis during temperature fluctuation. However, how warming mediates shrimp health remains poorly understood.

Annealing Study on Praseodymium-Doped Indium Zinc Oxide Thin-Film Transistors and Fabrication of Flexible Devices.

The praseodymium-doped indium zinc oxide (PrIZO) thin-film transistor (TFT) is promising for applications in flat-panel displays, due to its high carrier mobility and stability. Nevertheless, there are few studies on the mechanism of annealing on PrIZO films and the fabrication of flexible devices. In this work, we first optimized the annealing-process parameters on the glass substrate.

Safety and Immunogenicity of the Tetravalent Recombinant COVID-19 Protein Vaccine SCTV01E in Children and Adolescents Aged 3 to 17 Years: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial.

: SCTV01E is a tetravalent recombinant COVID-19 vaccine authorized for emergency use in China for adults 18 years and older but not for those under 18. : This Phase 2 trial assessed the safety and immunogenicity of SCTV01E in healthy children and adolescents aged 3 to 17 years, to establish immunobridging with that observed in adults from the efficacy pivotal trial (NCT05308576). : Participants were randomly assigned to receive either 30 µg of SCTV01E or a placebo.